scholarly journals A Scoping Review Examining the Integration of Exercise Services in Clinical Oncology Settings

2021 ◽  
Author(s):  
Elochukwu F. Ezenwankwo ◽  
Daniel A. Nnate ◽  
Godspower D. Usoro ◽  
Chimdimma P. Onyeso ◽  
Ijeoma B. Anieto ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Clinical Oncology ◽  
Hospital Readmission ◽  
Service Integration ◽  
Organizational Dynamics ◽  
Exercise Medicine ◽  
Barriers To Service ◽  
Private Donations ◽  
Exercise Oncology ◽  
Practical Recommendations

Abstract Background: Addressing questions surrounding the feasibility of embedding exercise service units in clinical oncology settings is imperative for developing a sustainable exercise-oncology clinical pathway. We examined available literature and provided practical recommendations to inform evidence-based practice, policymaking, and further investigations. Methods: Studies that recruited cancer patients, assessed the co-location of exercise services and cancer treatment units and reported findings on service implementation were included. Evidence from six studies providing data from over 30 programs was integrated using narrative synthesis. Results: Exercise service implementation was relatively modest across the included studies. These services were delivered by physiotherapists, exercise physiologists, and kinesiologists and funded mainly through grants and private donations, with staff salaries accruing as the major expense. Service penetration, adoption, and acceptability were generally low. However, studies recorded high clinician/patient satisfaction. Major barriers to service integration were limited funding, lack of detailed implementation plan, and low organizational buy-in. Common reasons for non-utilization, missed sessions, and dropouts were lack of interest, unwellness, hospital readmission, disease progression, and adverse skeletal events. Conclusion: Implementing exercise services in clinical oncology settings seems an effective approach for increasing access to exercise medicine for individuals on cancer treatment. While this model appears feasible for patients/clinicians, calculated efforts are required to drive uptake. There is no one-size-fits-all approach; hence, sustainable service integration remains a product of many factors, including structures and strategies that reflect the organizational dynamics of the clinical service environment housing the exercise unit.

scholarly journals Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology

2016 ◽  
Vol 12 (12) ◽  
pp. 1215-1218 ◽  
Author(s):  
Charles W. Given ◽  
Barbara A. Given ◽  
Cathy J. Bradley ◽  
John C. Krauss ◽  
Alla Sikorskii ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Clinical Oncology ◽  
European Society ◽  
Medical Oncology ◽  
Dynamic Assessment ◽  
American Society

scholarly journals Targeted Exercise Training for Cancer Patients: Moving beyond Generic Exercise Guidelines in Clinical Oncology

2021 ◽  
pp. 43-52
Author(s):  
Ciaran M Fairman ◽  
Jesper F Christensen
Keyword(s):  
Physical Activity ◽  
South Carolina ◽  
Exercise Training ◽  
Cancer Patients ◽  
Clinical Oncology ◽  
Exercise Prescription ◽  
Exercise Interventions ◽  
Sports Science ◽  
Exercise Guidelines ◽  
Exercise Oncology

Targeted Exercise Training for Cancer Patients: Moving beyond Generic Exercise Guidelines in Clinical Oncology Ciaran M Fairman1 and Jesper F Christensen()2,3  1Department of Exercise Science, University of South Carolina, USA 2Center for Physical Activity Research, Rigshospitalet, Copenhagen, Denmark 3Department of Sports Science and Clinical Biomechanics, Faculty of Health Sciences, University of Southern Denmark, Denmark © The Authors   Abstract The field of exercise oncology has rapidly evolved over the past 30 years. Initial investigations of safety and feasibility have progressed towards efficacy and effectiveness trials with a variety of health-related outcomes in mind. More recently, it has been recognized that interventions aimed at modifying physical activity behavior (i.e. behavioral interventions to increase participation in un/structured physical activity) are distinctly different from those aiming to target a clinically relevant outcome (using a specific exercise prescription). There is a strong rationale for the latter, where cancer/treatment toxicities can result in musculoskeletal, cardiopulmonary, and/or hematological declines with important prognostic implications. Treatment intolerance, unfavorable tumor response and heightened risk of mortality are all consequences of leaving these impairments unaddressed. Importantly, the control/reversal of the decline in these systems is more likely to occur through a targeted exercise prescription, specifically designed to target the impairment, rather than interventions trying to change behavior. This requires careful consideration in the study design in exercise oncology in relation to the selection of clinically relevant outcomes, decisions on methods of assessments and ensuring the exercise is targeted to the outcome.     The objective of this review is to 1) conceptualize and provide a clinical rationale for targeted exercise interventions in exercise oncology, and 2) provide a framework for consideration in the design and execution in targeted exercise interventions in oncology. We hope that this framework can encourage research into targeted exercise interventions in oncology and that our framework can be used to inform the design of future trials.

scholarly journals PRISMA Analysis of 30 Day Readmissions to a Tertiary Cancer Hospital

2015 ◽  
Vol 14 (2) ◽  
pp. 53-56
Author(s):  
Timothy Cooksley ◽  
◽  
Hanneke Merten ◽  
John Kellett ◽  
Mikkel Brabrand ◽  
...  
Keyword(s):  
Human Factors ◽  
Cancer Treatment ◽  
Quality Indicator ◽  
Hospital Readmission ◽  
Medical Condition ◽  
Hospital Readmissions ◽  
Underlying Condition ◽  
Patients With Cancer ◽  
Cancer Hospital ◽  
Increased Risk

Background: Hospital readmissions are increasingly used as a quality indicator. Patients with cancer have an increased risk of readmission. The purpose of this study was to develop an in depth understanding of the causes of readmissions in patients undergoing cancer treatment using PRISMA methodology and was subsequently used to identify any potentially preventable causes of readmission in this cohort. Methods: 50 consecutive 30 day readmissions from the 1st November 2014 to the medical admissions unit (MAU) at a specialist tertiary cancer hospital in the Northwest of England were analysed retrospectively. Results: 25(50%) of the patients were male with a median age of 59 years (range 19-81). PRISMA analysis showed that active (human) factors contributed to the readmission of 4 (8%) of the readmissions, which may have been potentially preventable. All of the readmissions were driven by a medical condition related to the patient’s underlying cancer and ongoing cancer treatment. Conclusion: The majority of readmissions of patients undergoing cancer treatment appear to be related to the underlying condition and, as such, are predictable but not preventable. This suggests that hospital readmission is not a good quality indicator in this cohort of patients.

Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA6009-CRA6009
Author(s):  
Joseph M Unger ◽  
Dawn L. Hershman ◽  
Kenda Burg ◽  
Carol Moinpour ◽  
Kathy S. Albain ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Decision Making ◽  
Cancer Treatment ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Trial Participation ◽  
Clinical Trial Participation ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

CRA6009 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News

Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

2008 ◽  
Vol 26 (2) ◽  
pp. 313-325 ◽  
Author(s):  
Julie Gralow ◽  
Robert F. Ozols ◽  
Dean F. Bajorin ◽  
Bruce D. Cheson ◽  
Howard M. Sandler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Clinical Trials ◽  
Cancer Treatment ◽  
Clinical Oncology ◽  
Major Research ◽  
Clinical Cancer Research ◽  
The Past ◽  
Clinical Cancer ◽  
American Society

A MESSAGE FROM ASCO'S PRESIDENTFor the third year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer Advances: Major Research Advances in Cancer Treatment, Prevention, and Screening, an annual review of the most significant cancer research presented or published over the past year. ASCO publishes this report to demonstrate the important progress being made on the front lines of clinical cancer research today. The report is intended to give all those with an interest in cancer care—the general public, cancer patients and organizations, policymakers, oncologists, and other medical professionals—an accessible summary of the year's most important cancer research advances. These pages report on the use of magnetic resonance imaging for breast cancer screening, the association between hormone replacement therapy and breast cancer incidence, the link between human papillomavirus and head and neck cancers, and the use of radiation therapy to prevent lung cancer from spreading. They also report on effective new targeted therapies for cancers that have been historically difficult to treat, such as liver cancer and kidney cancer, among many others. A total of 24 advances are featured in this year's report. These advances and many more over the past several years show that the nation's long-term investment in cancer research is paying off. But there are disturbing signs that progress could slow. We are now in the midst of the longest sustained period of flat government funding for cancer research in history. The budgets for the National Institutes of Health and the National Cancer Institute (NCI) have been unchanged for four years. When adjusted for inflation, cancer research funding has actually declined 12% since 2004. These budget constraints limit the NCI's ability to fund promising cancer research. In the past several years the number of grants that the NCI has been able to fund has significantly decreased; this year, in response to just the threat of a 10% budget cut, the nation's Clinical Trials Cooperative Groups reduced the number of patients participating in clinical trials by almost 2,000 and senior researchers report that many of the brightest young minds no longer see the promise of a career in science, choosing other careers instead. It's time to renew the nation's commitment to cancer research. Without additional support, the opportunity to build on the extraordinary progress to date will be lost or delayed. This report demonstrates the essential role that clinical cancer research plays in finding new and better ways to care for the more than 1.4 million people expected to be diagnosed with cancer this year. I want to thank the Editorial Board members, the Specialty Editors, and the ASCO Cancer Communications Committee for their dedicated work to develop this report. I hope you find it useful. Sincerely, Nancy E. Davidson, MD President American Society of Clinical Oncology

scholarly journals The impact of a hospital-based exercise oncology program on cancer treatment–related side effects among rural cancer survivors

2021 ◽  
Author(s):  
Adriana M. Coletta ◽  
Nathan B. Rose ◽  
Austin F. Johnson ◽  
D. Scott Moxon ◽  
Stephen K. Trapp ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Physical Function ◽  
Univariate Analysis ◽  
Whole Body ◽  
Initial Assessment ◽  
Muscular Endurance ◽  
The Impact ◽  
Exercise Oncology

Abstract Purpose To assess the impact of the Personal Optimism With Exercise Recovery (POWER) program on cancer treatment–related side effects among rural cancer survivors. Methods In this retrospective study of data collected between 2016 and 2019, we assessed change in cardiorespiratory fitness, whole-body muscular endurance, physical function and strength, anthropometrics, fatigue, and quality of life (QoL), after participation in POWER. Descriptive statistics were calculated for demographic and clinical variables. Univariate analysis of variance was carried out with age and BMI at initial assessment as covariates. Results A total of 239 survivors, 78% rural residents, completed a follow-up assessment. Among rural cancer survivors, the most prevalent cancer sites were breast (42.5%), prostate (12.4%), and lymphoma (5.9%). The majority of survivors were female (70%), non-Hispanic (94.6%), and white (93.5%), with average age and BMI of 62.1 ± 13.2 years and 28.4 ± 6.7 kg/m2, respectively. Rural cancer survivors with cancer stages I–III exhibited significant improvements in fitness (+ 3.07 ml/kg/min, 95% CI 1.93, 4.21; + 0.88 METS, 95% CI 0.55, 1.20), physical function (30-s chair stand: + 2.2 repetitions, 95% CI 1.3, 3.1), muscular endurance (10-repetition maximum: chest press + 4.1 kg, 95% CI 2.0, 6.3; lateral pulldown + 6.6 kg, 95% CI 4.4, 8.9), self-reported fatigue (FACIT-Fatigue score: + 4.9, 95% CI 1.6, 8.1), and QoL (FACT-G7 score + 2.1, 95% CI, 0.9, 3.4). Among stage IV rural and urban cancer survivors, significant improvements were observed in muscular endurance and physical function. Conclusion Participation in POWER was associated with attenuation of cancer treatment–related side effects and may serve as a model exercise oncology program for rural cancer survivors.

scholarly journals Cardiorespiratory considerations for return-to-play in elite athletes after COVID-19 infection: a practical guide for sport and exercise medicine physicians

2020 ◽  
Vol 54 (19) ◽  
pp. 1157-1161 ◽  
Author(s):  
Mathew G Wilson ◽  
James H Hull ◽  
John Rogers ◽  
Noel Pollock ◽  
Miranda Dodd ◽  
...  
Keyword(s):  
Elite Athletes ◽  
Return To Play ◽  
Infection Rates ◽  
Cardiorespiratory System ◽  
Residual Symptoms ◽  
Viral Spread ◽  
Exercise Medicine ◽  
Sport And Exercise ◽  
New Evidence ◽  
Practical Recommendations

SARS-CoV-2 is the causative virus responsible for the COVID-19 pandemic. This pandemic has necessitated that all professional and elite sport is either suspended, postponed or cancelled altogether to minimise the risk of viral spread. As infection rates drop and quarantine restrictions are lifted, the question how athletes can safely resume competitive sport is being asked. Given the rapidly evolving knowledge base about the virus and changing governmental and public health recommendations, a precise answer to this question is fraught with complexity and nuance. Without robust data to inform policy, return-to-play (RTP) decisions are especially difficult for elite athletes on the suspicion that the COVID-19 virus could result in significant cardiorespiratory compromise in a minority of afflicted athletes. There are now consistent reports of athletes reporting persistent and residual symptoms many weeks to months after initial COVID-19 infection. These symptoms include cough, tachycardia and extreme fatigue. To support safe RTP, we provide sport and exercise medicine physicians with practical recommendations on how to exclude cardiorespiratory complications of COVID-19 in elite athletes who place high demand on their cardiorespiratory system. As new evidence emerges, guidance for a safe RTP should be updated.

Sign in / Sign up

Export Citation Format

Share Document